Antibody–Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?
Multiple myeloma is a malignancy of immunoglobulin-secreting plasma cells that is now often treated in the newly diagnosed and relapsed and/or refractory settings with monoclonal antibodies targeting lineage-specific markers used either alone or in rationally designed combination regimens. Among the...
Na minha lista:
| Principais autores: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI AG
2023-04-01
|
| coleção: | Pharmaceuticals |
| Assuntos: | |
| Acesso em linha: | https://www.mdpi.com/1424-8247/16/4/590 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|